SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of NUVASIVE (Nasdaq – NUVA)

BALA CYNWYD – February 9, 2023 /Newsfile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of NUVASIVE (“NUVASIVE” or the “Company”) (Nasdaq – NUVA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by Globus Medical (NYSE – GMED). Under the terms of the agreement, NUVASIVE shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NUVASIVE common stock owned at the closing of the transaction. Based on this exchange ratio, the implied share price for NUVASIVE would be $57.72, an equity value of $3.1 billion, based on Globus Medical’s closing share price on February 8. Following the close of the transaction, NUVASIVE shareholders will own approximately 28% of the combined company, and Globus Medical shareholders will own approximately 72%, on a fully diluted basis.

The investigation concerns whether the NUVASIVE Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Globus Medical is paying too little for the Company.

If you own shares of NUVASIVE stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.